A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05923008 |
Recruitment Status :
Recruiting
First Posted : June 28, 2023
Last Update Posted : November 29, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Solid Tumor | Drug: IBI130 | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 182 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1/2, Multicenter, Open-label Study of IBI130 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors |
Actual Study Start Date : | November 14, 2023 |
Estimated Primary Completion Date : | November 30, 2024 |
Estimated Study Completion Date : | October 31, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: IBI130
IBI130
|
Drug: IBI130
Subjects will receive IBI130 until unacceptable toxicity, disease progression, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or for a maximum of 24 months of treatment, whichever occurs first. |
- Adverse events (AEs) [ Time Frame: Up to 30 days post last dose ]Adverse events will be assessed by investigator(s) according to NCI-CTCAE v5.0
- objective response rate (ORR) [ Time Frame: Time from first dose to best response to treatment, assessed up to 3 years ]ORR is the percentage of complete response(CR) plus partial response assessed(PR) per RECIST v1.1 criteria
- duration of response(DoR) [ Time Frame: Duration of response from the first documentation of objective response (confirmed CR or PR) to the first documented disease progression, assessed up to 3 years ]For subjects with CR or PR,duration of response(DoR) is the time from the first documented CR or PR to disease progression assessed per RESICT v1.1 criteria or death
- overall survival (OS) [ Time Frame: Time from first dose to death, assessed up to 3 years ]Time from the date of the first dose to death of the subject due to any cause
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subjects with the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol;
- Male or female subjects ≥ 18 years old;
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;
- Anticipated life expectancy of ≥ 12 weeks;
- Adequate bone marrow and organ function
Exclusion Criteria:
- Enrolled in any other interventional clinical research except unless only involved in an observational study (non-interventional) or in the follow-up phase of an interventional study;
- Received previous anti-tumor therapy within 4 weeks or 5 half-lives of the anti-tumor regimens before the first administration of study drug, whichever is shorter;
- Plan to receive other antitumor therapy during the study excluding palliative radiotherapy for the purpose of symptom (like pain) relief that must also do not have impact on tumor assessment throughout the study;
- Received live vaccines within 4 weeks prior to first administration of the study drug or plan on receiving any live vaccine during the study;
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05923008
Contact: Serena Dong | 0512 69566088 | suhua.dong@innoventbio.com |
Australia, Queensland | |
Sunshine Coast University | Recruiting |
Birtinya, Queensland, Australia, 4575 | |
Contact: Michelle Morris 07 53906057 morrismi2@ramsayhealth.com.au |
Responsible Party: | Innovent Biologics (Suzhou) Co. Ltd. |
ClinicalTrials.gov Identifier: | NCT05923008 |
Other Study ID Numbers: |
CIBI130A101 |
First Posted: | June 28, 2023 Key Record Dates |
Last Update Posted: | November 29, 2023 |
Last Verified: | November 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Neoplasms |